Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc (BEAM)
26.40 x 1 29.00 x 1
Post-market by (Cboe BZX)
28.48 +1.23 (+4.51%) 03/07/25 [NASDAQ]
26.40 x 1 29.00 x 1
Post-market 28.49 +0.01 (+0.04%) 19:15 ET
Quote Overview for Fri, Mar 7th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
26.54
Day High
29.05
Open 26.89
Previous Close 27.25 27.25
Volume 1,329,700 1,329,700
Avg Vol 1,542,620 1,542,620
Stochastic %K 31.41% 31.41%
Weighted Alpha -17.32 -17.32
5-Day Change +2.14 (+8.12%) +2.14 (+8.12%)
52-Week Range 20.84 - 38.99 20.84 - 38.99
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,383,435
  • Shares Outstanding, K 83,688
  • Annual Sales, $ 63,520 K
  • Annual Income, $ -376,740 K
  • EBIT $ -416 M
  • EBITDA $ -416 M
  • 60-Month Beta 1.91
  • Price/Sales 35.90
  • Price/Cash Flow N/A
  • Price/Book 3.08

Options Overview Details

View History
  • Implied Volatility 103.61% ( +9.97%)
  • Historical Volatility 70.38%
  • IV Percentile 99%
  • IV Rank 97.38%
  • IV High 105.44% on 02/21/25
  • IV Low 35.30% on 05/31/24
  • Put/Call Vol Ratio 2.11
  • Today's Volume 3,755
  • Volume Avg (30-Day) 1,337
  • Put/Call OI Ratio 0.55
  • Today's Open Interest 16,404
  • Open Int (30-Day) 13,465

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.17
  • Number of Estimates 5
  • High Estimate -0.94
  • Low Estimate -1.34
  • Prior Year -1.21
  • Growth Rate Est. (year over year) +3.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.63 +20.52%
on 03/04/25
Period Open: 27.41
35.25 -19.21%
on 02/18/25
+1.07 (+3.90%)
since 02/07/25
3-Month
22.50 +26.58%
on 01/15/25
Period Open: 26.71
35.25 -19.21%
on 02/18/25
+1.77 (+6.63%)
since 12/06/24
52-Week
20.84 +36.66%
on 04/25/24
Period Open: 36.96
38.99 -26.96%
on 03/08/24
-8.48 (-22.94%)
since 03/07/24

Most Recent Stories

More News
Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

BEAM : 28.48 (+4.51%)
Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

BEAM : 28.48 (+4.51%)
Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

BEAM : 28.48 (+4.51%)
Is it a Good Idea to Invest in Beam Therapeutics Stock Now?

Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON study for treating sickle cell disease (SCD), an inherited blood disorder.BEAM’s...

BEAM : 28.48 (+4.51%)
VYGR : 4.26 (+2.90%)
CSTL : 20.21 (-1.85%)
HRMY : 33.67 (-0.12%)
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

BEAM : 28.48 (+4.51%)
Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now?

One stock that might be an intriguing choice for investors right now is Beam Therapeutics Inc. BEAM This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings...

BEAM : 28.48 (+4.51%)
Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

BEAM : 28.48 (+4.51%)
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BEAM : 28.48 (+4.51%)
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up

Shares of Beam Therapeutics Inc. BEAM were up 5.5% on Dec. 6 after the company announced that it has appointed Sravan K. Emany as its new chief financial officer (CFO).He will assume his new role on Dec....

BEAM : 28.48 (+4.51%)
IMCR : 29.80 (-3.28%)
CSTL : 20.21 (-1.85%)
SPRO : 0.7790 (-1.14%)
Beam Therapeutics Reports Successful Preclinical Data on CD117 mAb Conditioning for Base-Edited Hematopoietic Stem Cell Therapy

Beam Therapeutics announced successful long-term engraftment of base-edited stem cells using anti-CD117 mAb conditioning in preclinical studies.Quiver AI SummaryBeam Therapeutics has announced promising...

BEAM : 28.48 (+4.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 32.02
2nd Resistance Point 30.53
1st Resistance Point 29.51
Last Price 28.48
1st Support Level 27.00
2nd Support Level 25.51
3rd Support Level 24.49

See More

52-Week High 38.99
Fibonacci 61.8% 32.06
Fibonacci 50% 29.92
Last Price 28.48
Fibonacci 38.2% 27.77
52-Week Low 20.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
How to Trade Futures Spreads Like a Pro – Unlock Powerful Market Insights